Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:QLGN

Qualigen Therapeutics 11/14/2025 Earnings Report

Qualigen Therapeutics logo
$1.23 -0.05 (-3.91%)
As of 05/18/2026
ProfileEarnings HistoryForecast

Qualigen Therapeutics EPS Results

Actual EPS
-$4.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Qualigen Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Qualigen Therapeutics Announcement Details

Quarter
Date
11/14/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Qualigen Therapeutics Earnings Headlines

Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19
December 13, 2025  |  cnn.comhttps://www.cnn.com/business/newsfeeds/prnewswire/202006100800PR_NEWS_USPR_____LA30398.html
Qualigen Therapeutics Rebrands to AIxCrypto Holdings
November 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/qualigen-therapeutics-rebrands-to-aixcrypto-holdings/ar-AA1QBc7y
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
 |  Porter & Company (Ad)
Qualigen Therapeutics stockholders approve all proposals with majority vote
November 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/qualigen-therapeutics-stockholders-approve-all-proposals-with-majority-vote/ar-AA1QyILE
Faraday Future Becomes Majority Shareholder in Qualigen Therapeutics, Preparing for Corporate Rebranding and Strategic Transformation on November 20
November 16, 2025  |  quiverquant.comQ
Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy
November 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/16/3188761/0/en/qualigen-therapeutics-stockholders-approve-all-proposals-with-majority-vote-company-to-rebrand-as-aixcrypto-holdings-inc-nasdaq-aixc-following-november-20-nasdaq-ceremony-and-annou.html
See More Qualigen Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Qualigen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qualigen Therapeutics and other key companies, straight to your email.

About Qualigen Therapeutics

Qualigen Therapeutics (NASDAQ:QLGN) (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories. These products support the detection and quantification of biomarkers ranging from infectious disease antigens to tumor-associated proteins. Qualigen’s diagnostic portfolio is sold to reference laboratories, hospital systems and point-of-care facilities across North America, Europe and select markets in Asia.

Qualigen BioTherapeutics is focused on developing a pipeline of antibody-based and cell-based immunotherapies targeting both hematologic and solid tumors. Its preclinical programs include monoclonal antibodies directed against validated cancer antigens as well as engineered cell therapies designed to enhance tumor recognition and cytotoxicity. The company applies proprietary protein conjugation and high-throughput screening platforms to advance candidates from lead identification through IND-enabling studies.

View Qualigen Therapeutics Profile
Earnings Tools